REGEnLIFE

About:

MedTech company focused on neurodegenerative diseases

Website: https://regenlife.com

Twitter/X: regenlife1

Description:

REGEnLIFE develops a cutting-edge photomedical neurotechnology for the treatment of neurodegenerative diseases. REGEnLIFE is a late-stage medical technology company currently focused on the treatment of Alzheimer's disease and mild traumatic brain injury (which can lead to dementia). The medical device is a patented therapeutic solution based on biophotonics. This non-invasive and painless application targets both the brain and the gut. Recent scientific studies suggest that the brain-gut axis plays a key role in the development of neurodegenerative diseases.

Total Funding Amount:

8.3M EUR

Headquarters Location:

Paris, Ile-de-France, France

Founded Date:

2016-01-19

Contact Email:

contact(AT)regenlife.com

Founders:

Guillaume Blivet

Number of Employees:

1-10

Last Funding Date:

2023-05-12

IPO Status:

Private

Industries:

© 2025 bioDAO.ai